Pharmaceutical Executive Spotlights Patient Advocacy and the New Faces of Change in Latest Issue
Pharm Exec spoke with leaders in a resurgent patient movement about compassionate use access to new drugs, clinical trial participation policy, and the individual unmet needs of patients suffering from dementia and cancer.
Pharmaceutical Executive, the biopharmaceutical industry's premier publication, spoke with leaders in a resurgent patient movement about matters of life and death: compassionate use access to new drugs, clinical trial participation policy, and the individual unmet needs of patients suffering from dementia and cancer.
Pleas for compassionate use access are on the increase, and Change.org is giving patients an audience. In THE ACTIVE PATIENT: FACES OF CHANGE, PharmExec's feature story, Brianna Cayo-Cotter, Change.org's managing director of communications, says one successful petition often begets another. Politicians and celebrities, in unprecedented fashion, are coming out in support of compassionate use petitions.
"We call it wildfire," says Cayo-Cotter. "When one person starts a petition for access to a drug, you'll start to see dozens and dozens of petitions...that ends up creating a space for there to be a real policy change, or an industry shift around an issue."
Like the AIDS activist groups ACT UP and TAG, and their impact on US compassionate use policy in the 1980s, Change.org is in a position to push regulators and the drug industry to rethink issues that separate the medical establishment from its patients.
"Anybody can use Change.org," says Cayo-Cotter. "It can raise a patient's profile in a way that was impossible even three years ago."
"Patient advocacy groups are expanding beyond the traditional boundaries and roles that used to separate individual players in the healthcare system," says PharmExec editor-in-chief William Looney. "There's no commodity more valuable than human health. Expect patient advocacy efforts to continue expanding into areas including R&D, healthcare delivery and global access policy."
Other patient advocates profiled in THE ACTIVE PATIENT: FACES OF CHANGE include Camila Strassle, an advocate working with the Cystic Fibrosis Foundation; Susan Grant, a patient and filmmaker promoting public awareness of frontotemporal dementia; and Sarah Krug, executive director at Cancer101, an organization that provides education to cancer patients based on individual needs.
For more information, contact: Ben Comer (212) 951-6738, [email protected]
Read more news from Pharmaceutical Executive.
Empowering Sites and Patients: The Impact of Personalized Support in Clinical Trials
November 26th 2024To meet the growing demands of clinical research, sponsors must prioritize comprehensive support models, such as clinical site ambassadors and patient journey coordinators, who can address operational challenges and improve site relationships, patient satisfaction, and overall trial efficiency.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
FDA Finalizes Decentralized Clinical Trial Guidance
November 25th 2024The FDA's guidance is part of a broader effort to modernize clinical trials, improve efficiency, reduce participant burden, and expand access, particularly for underrepresented populations and those in geographically or economically constrained areas.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
